Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-15 4:45 pm Purchase | 13D | MERSANA THERAPEUTICS INC MRSN | Bain Capital Life Sciences Fund II L.P. | 4,968,006 4.000% | 926,273 (+22.92%) | View |
| 2024-11-14 5:44 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | Bain Capital Life Sciences Fund II L.P. | 4,566,817 11.000% | 3,218,135 (+238.61%) | View |
| 2024-11-14 5:24 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Bain Capital Life Sciences Fund II L.P. | 2,750,151 11.000% | 343 (+0.01%) | View |
| 2024-04-12 5:26 pm Purchase | 13D | Savara Inc SVRA | Bain Capital Life Sciences Fund II L.P. | 14,565,457 13.000% | 332,706 (+2.34%) | View |
| 2024-03-29 5:16 pm Unchanged | 13D | Nuvalent Inc. NUVL | Bain Capital Life Sciences Fund II L.P. | 2,400,630 4.100% | 0 (Unchanged) | View |
| 2024-02-13 6:59 pm Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Bain Capital Life Sciences Fund II L.P. | 2,749,808 11.000% | 625,114 (+29.42%) | View |
| 2023-10-20 4:30 pm Unchanged | 13D | Nuvalent Inc. NUVL | Bain Capital Life Sciences Fund II L.P. | 2,400,630 4.200% | 0 (Unchanged) | View |
| 2023-07-19 4:30 pm Purchase | 13D | Savara Inc SVRA | Bain Capital Life Sciences Fund II L.P. | 14,232,751 13.000% | 2,610,153 (+22.46%) | View |
| 2023-02-14 06:15 am Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Bain Capital Life Sciences Fund II L.P. | 2,124,694 11.000% | 2,124,694 (New Position) | View |
| 2022-11-03 4:15 pm Unchanged | 13D | Nuvalent Inc. NUVL | Bain Capital Life Sciences Fund II L.P. | 2,400,630 4.800% | 0 (Unchanged) | View |
| 2022-05-11 5:26 pm Unchanged | 13D | MERSANA THERAPEUTICS INC MRSN | Bain Capital Life Sciences Fund II L.P. | 4,041,733 4.200% | 0 (Unchanged) | View |
| 2022-04-14 4:56 pm Purchase | 13D | MERSANA THERAPEUTICS INC MRSN | Bain Capital Life Sciences Fund II L.P. | 4,041,733 4.800% | 747,310 (+22.68%) | View |
| 2022-02-14 06:42 am Unchanged | 13G | Xilio Therapeutics Inc. XLO | Bain Capital Life Sciences Fund II L.P. | 1,348,682 4.900% | 0 (Unchanged) | View |
| 2022-02-14 06:41 am Purchase | 13G | Syros Pharmaceuticals Inc. SYRS | Bain Capital Life Sciences Fund II L.P. | 6,264,420 11.000% | 479,384 (+8.29%) | View |
| 2022-02-08 5:02 pm Unchanged | 13D | MERSANA THERAPEUTICS INC MRSN | Bain Capital Life Sciences Fund II L.P. | 3,294,423 4.400% | 0 (Unchanged) | View |
| 2022-01-03 5:10 pm Unchanged | 13D | MERSANA THERAPEUTICS INC MRSN | Bain Capital Life Sciences Fund II L.P. | 3,294,423 4.500% | 0 (Unchanged) | View |
| 2021-11-05 5:16 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | Bain Capital Life Sciences Fund II L.P. | 1,348,682 5.100% | 1,348,682 (New Position) | View |
| 2021-09-24 5:15 pm Sale | 13D | Atea Pharmaceuticals Inc. AVIR | Bain Capital Life Sciences Fund II L.P. | 3,178,532 3.800% | -846,856 (-21.04%) | View |
| 2021-09-03 5:00 pm Sale | 13D | Atea Pharmaceuticals Inc. AVIR | Bain Capital Life Sciences Fund II L.P. | 4,025,388 4.900% | -757,714 (-15.84%) | View |
| 2021-08-04 5:11 pm Purchase | 13D | Nuvalent Inc. NUVL | Bain Capital Life Sciences Fund II L.P. | 2,400,630 5.600% | 2,400,630 (New Position) | View |